Paradoxically, univariate and multivariate analysis of 92 patients with MDS revealed DNMT3A mutations were correlated with better overall response rate (ORR) and progression-free survival (PFS) (Traina et al., 2013). This evidence concerns the gene DNMT3A and myelodysplastic syndrome.